Drugs / Live attenuated Japanese encephalitis vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT04111432 | Jul → Nov 2019 | hand, foot and mouth disease | Sinovac Biotech Co., Ltd | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT03296410 Comparator | Sep 2017 → Sep 2019 | hand, foot and mouth disease | Chinese Academy of Medical Sciences | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Live attenuated Japanese encephalitis vaccine | “The MMR vaccine was manufactured by Shanghai Institute of Biological Products Co.,Ltd.; the Live attenuated Japanese encephalitis vaccine was manufactured by Chengdu Institute...” NCT04111432 ↗ |
| Known as | encephalitis live attenuated vaccine | “EV71 vaccine (second dose)\&encephalitis live attenuated vaccine on day 30” NCT04111432 ↗ |
| Modality | Vaccine | “live attenuated Japanese encephalitis vaccine” NCT03296410 ↗ |
| Route | Subcutaneous | “encephalitis live attenuated vaccine (subcutaneous injection, 0.5ml)” NCT04111432 ↗ |